Micot Pharma's MT200605 Achieves Primary Endpoint in Phase II Trial, Novel Integrated Multi-stage Neuroprotection Mechanism to Be Presented at WSC 2026Asian Corporate Newswire·2 days ago, 08:01 AM02335+111.00%
Shaanxi Micot’s Stroke Drug MT200605 Hits Phase II Milestone, Bolstering Neuro PortfolioTip Ranks·Aug 3 at 10:22 AM02335+111.00%
Shaanxi Micot says Phase II trial database lock completed for stroke drug candidate MT200605PUBT·Jul 24 at 06:41 AM02335+111.00%
Hong Kong stock movement: MICOT PHARMA-B fell by 15.32%, with increased volatility in capital activityHK Stock Alerts·Jul 19 at 10:57 PM02335+111.00%
Hong Kong stock movement: MICOT PHARMA-B fell 10.08%, with increased volatility in capital activityHK Stock Alerts·Jul 19 at 10:32 PM02335+111.00%
Shaanxi Micot enrolls first patient in Phase II trial of MT1002 anticoagulant in hemodialysis patientsPUBT·Jul 9 at 05:44 AM02335+111.00%
Mecox Pharma-B Starts Patient Enrollment in Phase Ib/II Trial of MT1002 for Acute Ischemic StrokeCoinLive·Jul 5 at 12:24 AM02335+111.00%
Shaanxi Micot enrolls first patient in Phase Ib/II MT1002 acute ischemic stroke trialPUBT·Jul 3 at 05:30 AM02335+111.00%
Shaanxi fund-backed Microcure Pharma lists in Hong Kong under Chapter 18A rulesPUBT·Jun 24 at 03:34 AM02335+111.00%
ZheShang Venture-backed Maike Pharma jumps 86.92% in Hong Kong debut after HKD 1.06 billion IPOPUBT·Jun 24 at 02:59 AM02335+111.00%
MICOT PHARMA-B1,181.46x Subscribed; 1-lot Success Rate Approx. 3%AASTOCKS News·Jun 23 at 09:00 PM02335+111.00%
Macro Flows Reshape HK Equities: Safe-Haven Premiums in Cross-Border Assets and Sector OutlookGlobal Report·Jun 20 at 04:24 AM01157-269.00%01276-162.00%
